Development of ORF2 gene vaccine against PCV2 and immunity test in mice

WANG Xin,GUO Wan-zhu,ZHOU Ting,XU Zhi-wen,WANG Yin,WANG Xiao-yu

DOI: https://doi.org/10.13207/j.cnki.jnwafu.2008.08.034

2008-01-01

Abstract:【Objective】 The study is to develop a new generation vaccine of PCV2 furtherly.【Method】 The ORF2 gene of PCV2 was inserted into the eukaryotic expression vector pcDNA-3.1(+) to construct nucleotide vaccine plasmid pcDNA-ORF2.The nucleotide vaccine plasmid identified by PCR and digestion was transfected into IBRS-2 cells with lipofectamine for the analysis of western blotting.The constructed pcDNA-ORF2 was developed into nucleotide vaccine to intramuscular inject into BALB/c mice with 100ug at two weeks interval.On the 14th and the 56th day after the first vaccination,serums were collected to test by ELISA.And on the 56th day after the first vaccination,cell mediated immunity was detected by MTT method and Fluorescence Activated Cell Sorter(FACS).To confirm the safety of pcDNA-ORF2 gene vaccines,the genomes of vaccinated mice were extracted for PCR amlification.【Result】 The result indicated that the nucleotide vaccine plasmid pcDNA-ORF2 was constructed successfully and the ORF2 gene was expressed in IBRS-2 cells,and pcDNA-ORF2 gene vaccines successfully induced humoral and cellular immune response in mice.The safety test of pcDNA-ORF2 gene vaccine showed that ORF2 genes could not be integrated into the mice chromosome and it was safe.【Conclusion】 The pcDNA-ORF2 gene vaccine successfully induced immune response in mice and was confirmed to be safe.